key: cord-0302910-ksqrt005
authors: Dasovich, Morgan; Zhuo, Junlin; Goodman, Jack A.; Thomas, Ajit; McPherson, Robert Lyle; Jayabalan, Aravinth Kumar; Busa, Veronica F.; Cheng, Shang-Jung; Murphy, Brennan A.; Redinger, Karli R.; Tsukamoto, Takashi; Slusher, Barbara; Bosch, Jürgen; Wei, Huijun; Leung, Anthony K. L.
title: High-throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain
date: 2021-10-11
journal: bioRxiv
DOI: 10.1101/2021.10.07.463234
sha: 42d896366a9c85d5737e301d74af8ead72507658
doc_id: 302910
cord_uid: ksqrt005

Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are critical for replication and virus-induced pathogenesis; therefore, these enzymes are a promising target for antiviral therapy. However, no potent or selective viral macrodomain inhibitors currently exist, in part due to the lack of a high-throughput assay for this class of enzymes. Here, we developed a high-throughput ADP-ribosylhydrolase assay using the SARS-CoV-2 macrodomain Mac1. We performed a pilot screen which identified dasatinib and dihydralazine as ADP-ribosylhydrolase inhibitors. Importantly, dasatinib does not inhibit MacroD2, the closest Mac1 homolog in humans. Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for screening large compound libraries to identify improved macrodomain inhibitors and explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats.

where only the first one (called Mac1) possesses ADPribosylhydrolase activity. [13] [14] [15] [16] [17] Notably, key residues critical for ADP-ribosylhydrolase activity are 100% conserved in all seven human coronaviruses as well as those identified from animal reservoirs, such as bat (Fig. S1 ). Macrodomain ADPribosylhydrolases are also conserved in another genus of pathogenic RNA viruses called alphaviruses (e.g. Chikungunya virus). 11, 12 Genetic evidence demonstrates the ADPribosylhydrolase activity of viral macrodomains is critical for replication and virulence. 11, 13, [18] [19] [20] [21] Mutant coronaviruses and alphaviruses cannot replicate when the ADP-ribosebinding sites within their macrodomains are disrupted. 11, 21 Additionally, macrodomain mutant viruses exhibit attenuated replication in differentiated cells and decreased virulence in vivo. 4, 5 Therefore, drugs targeting the ADPribosylhydrolase activity of viral macrodomains have the potential to inhibit viral replication and pathogenesis.

Two major challenges must be addressed during the development of antiviral macrodomain inhibitors. First, measurements of macrodomain ADP-ribosylhydrolase activity have historically relied on gel-based autoradiography and western blot assays that are not practical for screening large numbers of compounds. Second, humans express 11 proteins with macrodomain folds, such as MacroD2, which is the closest enzymatically-active human homolog of SARS-CoV-2 Mac1. 15 Therefore, compounds that non-specifically inhibit human macrodomains will likely have off-target effects that limit their utility. Here we describe a quantitative, high-throughput assay that identified virus-specific and general inhibitors of macrodomains. 

To explore whether selective inhibition of a viral macrodomain is possible, we began our investigation by identifying biochemical and structural differences between SARS-CoV-2 Mac1 and human MacroD2. Sequence analyses classified both Mac1 and MacroD2 macrodomains to the macroD-type subclass, which also includes the macrodomain from the Chikungunya virus. 3, 5 Given that the Chikungunya virus macrodomain hydrolyzes ADP-ribose from recombinant PARP10 catalytic domain 11, 12 and G3BP1 protein from cells, 22 we tested these substrates with Mac1 and MacroD2 ( Fig. 1A and S2A ). Following macrodomain incubation, comparable losses of ADP-ribose signal from PARP10 CD and G3BP1 were observed, indicating both SARS-CoV-2 Mac1 and human MacroD2 are active ADPribosylhydrolases.

To quantitatively measure the enzymatic activity with a high-throughput method, we developed the luminescence-based assay ADPr-Glo (Fig. 1B) : First, ADP-ribose is released from a defined protein substrate by the macrodomain ADP-ribosylhydrolase. Second, the phosphodiesterase NudF cleaves the released ADP-ribose into phosphoribose and AMP. Finally, AMP is converted to luminescence with the commercially available AMP-Glo kit. This method takes advantage of the substrate selectivity of NudF, which cleaves free ADP-ribose but has no activity with proteinconjugated ADP-ribose. 23 Therefore, the luminescence signal is controlled by the rate of the ADP-ribosylhydrolase. ADPr-Glo can be performed in 384-well plates with reaction volumes as low as 5 µL, greatly minimizing time and costs compared to gel-based activity assays.

We first used ADPr-Glo to measure the Michaelis-Menten kinetics of SARS-CoV-2 Mac1 and human MacroD2 with an ADP-ribosylated protein substrate. The KM of Mac1 was 178.5 ± 53.2 µM with a kcat of 2.1 ± 0.6 sec -1 (Fig. 1C) , and the KM of MacroD2 was 9.9 ± 4.6 µM with a kcat of 0.6 ± 0.03 sec -1 (Fig. 1D) . The lower KM of MacroD2 is consistent with its higher affinity for ADP-ribose monomers 16 and polymers ( Fig. 1E and S2B) . Therefore, SARS-CoV-2 Mac1 and human MacroD2 exhibit distinct binding and kinetic properties with free and protein-conjugated ADP-ribose, which likely reflect chemical and structural differences within their active sites.

Comparison of the published macrodomain structures of Mac1 and MacroD2 revealed that ~60% of residues at the ADP-ribose binding sites are conserved (Fig. 1F ). Similar to MacroD2 and the Chikungunya virus macrodomain, 9, 11 mutation of a conserved glycine residue to glutamate (G252E for SARS-CoV-2 nsp3, Fig. S1 ) abrogates the activity of Mac1 (Fig. S2C ). Incubation of Mac1 G252E with the ADPribosylated protein substrate followed by NudF addition yielded the same amount of signal as the NudF-only control. A closer examination of Mac1 and MacroD2 structures revealed less conserved regions (e.g., the adenosine binding pocket; Fig. 1F ) and distinctive electrostatic surfaces surrounding the active site where ADP-ribose binds (Fig. S2D) . Compared with MacroD2, Mac1 possesses a binding pocket with more charged surfaces that is 450 Å 3 larger ( Fig. 1G and S2D-E). Taken together, these functional and structural differences may permit selective inhibition of SARS-CoV-2 Mac1, but not human MacroD2.

We next established ADPr-Glo conditions for inhibitor screening ( Fig. 2A) . The reaction was linear with respect to enzyme concentration (0.5 nM) and time of incubation (60 min) at room temperature in the presence of 20 µM ADPribosylated substrates, 125 nM NudF and final DMSO concentration of 1%, with excellent reproducibility when performed over different dates (Fig. S3) . We then carried out a pilot screen of the 3,233 pharmacologically active compounds derived from the Selleck-FDA library (1,953) and the LOPAC library (1, 280) .

The pilot screen parameters were suitable for a large high-throughput screen with the coefficient of variation (CV) ranging from 1-4%, the screening window coefficient Z' at 0.86, and an average signal-to-background (S/B) ratio of 3.4 (Fig. 2B) . We calculated the average signal (A) and standard deviation (SD) of compound-treated wells in each plate and determined a Z score for each compound where Z=(signal-A)/SD (Fig. 2C) . Compounds with Z score ≤ -3 were considered hits (Supplementary Datafile 1). Our pilot screen at 100 µM identified 21 compounds from the Selleck-FDA library and 16 compounds from the LOPAC library with Z ≤ -3, resulting in a 1.2% hit rate. Notably, the kinase inhibitor dasatinib was present as three different forms in the FDA library (Supplementary Datafile 1), and all of them were identified as hits, indicating assay reproducibility. Among 37 total hits, 24 were excluded based on several criteria, including the presence of pan-assay interfering (PAINS) substructures and/or potential aggregators based on the ZINC filtering algorithm 24 , interference of luminescence detection, high-molecular weight, instrument issues or commercial availability (see Supplementary Datafile 1). The remaining 13 hits were either purchased in powder form or synthesized for further evaluation.

To identify false-positive hits that either inhibit NudF or interfere with AMP detection by AMP-Glo, we performed a counter screen where 2 µM ADP-ribose was used instead of the ADP-ribosylated substrate and the macrodomain was omitted from the reaction (Fig. S4A-F ). Four compounds demonstrated dose-dependent inhibition in the counter screen, indicating they are inhibitors of NudF and/or AMP-Glo ( Fig. S4B-E) . Vandetanib had poor solubility in aqueous solution (<10 µM) which prohibited dose-response analysis. The remaining six compounds did not inhibit the NudFmediated counter screen assay and were subsequently evaluated in a dose-response assay against SARS-CoV-2 Mac1 (Fig. S4F -I). Among the six remaining hits, only dasatinib and dihydralazine exhibited dose-dependent inhibition (Fig. 3A -B and S4G-I), with an IC50 of 37.5-57.5 µM and 485-757 µM (95% C.I.), respectively. We then evaluated these two inhibitors in an orthogonal gel-based activity assay. Consistent with its higher potency, only dasatinib mitigated the reduction of ADP-ribosylation under the tested conditions (Fig.  3C ).

To evaluate whether these drugs broadly inhibit ADPribosylhydrolases or are specific for Mac1, we replaced the SARS-CoV-2 macrodomain with human MacroD2 in our ADPr-Glo assay and tested for dose-dependent inhibition ( Fig. 3A-B) . Strikingly, dasatinib did not show any inhibition of MacroD2 even at 2 mM, the solubility limit of the compound in 2% DMSO. On the contrary, dihydralazine inhibited MacroD2 and Mac1 with comparable potency (IC50 = 500-1,830 µM, P = 0.82, t-test).

Because dasatinib was more potent and selective, we focused our efforts on investigating the dasatinib-macrodomain interaction. To directly assess the dasatinib binding to these two macrodomains, we performed Surface Plasmon Resonance (SPR) analyses. Both Mac1 and MacroD2 bound strongly to ADP-ribose ( Fig. 3D and S5), indicating that both macrodomains were properly folded and able to interact with small-molecule ligands in our SPR assays. Consistent with the selective inhibition observed in the ADPr-Glo assay, dasatinib bound ~3-fold more to Mac1 than MacroD2 ( Fig. 3E and S5 ). Molecular docking analyses revealed that dasatinib binds at the highly conserved ADP-ribose binding site ( Fig. 3F -H and S6, Supporting Datafile 2), which is supported by the lack of ADP-ribose and dasatinib binding by the active site mutant G252E (Fig. 3D -F and S5). Notably, ten of 25 dasatinib-contacting residues in Mac1 are not conserved in MacroD2 (Fig. 3G ), which may explain the selectivity.

Recent high-throughput efforts have used virtual and binding screens to identify compounds and fragments that bind to SARS-CoV-2 Mac1. [25] [26] [27] We directly compared dasatinib to the hits identified in these studies and found that dasatinib was a more potent ADP-ribosylhydrolase inhibitor ( Fig. 3I and S7A) and a stronger Mac1 binder (Fig. S7B) . Notably, dasatinib was not identified as a hit despite being included in libraries used by Schuller et al. One possibility is that dasatinib produced high fluorescence when mixed with SYPRO Orange, a dye commonly used in differential scanning fluorimetry (Fig. S7C ) and may therefore be a false negative in prior screens. These findings collectively highlight the novelty and benefits of our functional screening approach as a complement to existing screens that assay binding.

In summary, we have established a new functional assay to identify ADP-ribosylhydrolase inhibitors. Our facile and versatile assay identifies both specific and general ADPribosylhydrolase inhibitors. Our pilot screen identified dasatinib, whose selectivity demonstrates it is possible to discover drugs that specifically inhibit viral macrodomains. Although cytotoxic when used at µM concentration, 28 dasatinib has antiviral activities against SARS-CoV and MERS-CoV through an unknown mechanism. 29 Therefore, data presented in this study provide strong support for our target and assay strategy, which can be applied to a large-scale high-throughput screen for new and improved viral macrodomain inhibitors. As the macrodomain fold is highly conserved in all coronaviruses and alphaviruses, this screening tool represents an important step towards developing new broad-spectrum antivirals. 

The authors declare no competing financial interest.

We thank Drs Diane Griffin, Mohsen Badiee, Rachy Abraham for their critiques of the manuscript, the NudF expression construct from Dr. Sandra Gabelli, Lauren Bambarger for the initial testing of the luminescence-based assay, and Dr. Said Goueli for advice on the AMP-Glo assay.

ABBREVIATIONS ADP, adenosine diphosphate; SARS, severe acute respiratory syndrome; MERS, middle east respiratory syndrome; CoV, coronavirus; HIV, human immunodeficiency virus.

Table of Contents S2-12. Methods S13. Figure S1 S14. Figure S2 S15. Figure S3 S16. Figure S4 S17. Figure S5 & S6 S17-18. Figure S7 S2 Chemicals Dasatinib (Cat# S1021), dasatinib Monohydrate (Cat# S7782), vandetanib (Cat# S1046), pixantrone maleate (Cat# S5059), allopurinol (Cat# S1630) and fludarabine phosphate (Cat# S1229) were purchased from SelleckChem.com, Tyrphostin AG 490 (Cat# T3434) 

ADP-ribosylation of PARP10 catalytic domain was performed essentially as described by Alhammad et al. (2020) . PARP10 (10 µM) was incubated for 20 min at 37° C with NAD+ (1 mM) in reaction buffer (50 mM HEPES pH 7.2, 150 mM NaCl, 0.2 mM DTT, 0.02% NP-40).

Automodified PARP10 was then aliquoted and stored at -80 °C.

The SARS-CoV-2 and human macrodomains (1 µM) were incubated with ADP-ribosylated ADPr is produced from hydrolysis of mono-ADP-ribosylated substrates, then free ADPr is cleaved into AMP and phosphoribose by the NudF phosphodiesterase. AMP is then converted to luminescence with the AMP-Glo kit (Promega V5012). were performed in parallel as a negative control. Luminescence signal was converted to AMP generated via interpolation from an AMP standard curve. Data plotted are AMP generated by Mac1 and NudF, subtracted by AMP generated from NudF alone (n = 12, four technical replicates from three independent experiments, with each day represented by a different color).

Standard deviation from the mean is shown in gray. Kinetic parameters were calculated with a Michaelis-Menten non-linear regression in Prism 9.0 (GraphPad).

The 20-mer Cy5-PAR was prepared as described by Abraham et al. (2020) . Cy5-PAR (10 nM) was mixed with protein at the indicated concentration in binding buffer (10 mM Tris pH 7.5, 100 mM KCl, 1 mM EDTA, 0.1 mM DTT, 0.01 mg/mL BSA, 0.01% w/v OrangeG, 5% v/v glycerol) and incubated at ambient temperature for 1 h. Samples were separated with a native 5% trisacetate polyacrylamide gel (37.5:1 acrylamide:bis-acrylamide ratio) by applying 10 V per cm of gel in tris-acetate buffer (40 mM Tris, 2.5 mM EDTA, 20 mM acetate pH 7.8) for 45 min. Cy5 signal was detected with a Typhoon (Molecular Biosciences). Cy5 signal was quantified with ImageStudio (Li-Cor), then plotted in Prism 9.0 (GraphPad). Dissociation constants were calculated with a sigmoidal dose-response curve by measuring [protein] at which half of the Cy5-PAR is bound in Prism 9.0 (GraphPad). 

Demodification samples (13.33 pmol PARP10 CD per lane) were separated with SDS-PAGE using 4-12% BisTris gels in MOPS-Tris running buffer, then transferred onto PVDF membranes.

After a 4 °C overnight incubation in blocking solution (5% w/v non-fat dry milk in TBS-T + 0.02% w/v sodium azide), membranes immunoblotted using the mono-ADP-ribose detection reagent (2 µg/mL in blocking solution, Millipore MABE1076) for 1 h at ambient temperature. Following S8 three 5 min washes in TBS-T, membranes were immunoblotted with secondary anti-Rabbit IgG polyclonal antibody conjugated with IRdye 800 (1:10,000 in blocking solution, Li-Cor 926-32213) for 1 h at ambient temperature. Following three 5 min washes in TBS-T, membranes were visualized with an Odyssey and data were quantified in ImageStudio.

Beckman ECHO acoustic liquid handler was used to transfer 50 nL of DMSO (columns 1-2, 23- incubation, the plates were read in a BMG CLARIOStar luminometer and the full light captured from each well for 1 s. All incubations were carried out at room temperature. Unless specified, all reagents were dispensed using Thermo Scientific's Multidrop instruments. Also, following every reagent addition, the plates were spun down for 1 min at 150 x g.

All hits were then counter-screened to preclude assay-interfering compounds. Drugs were diluted to desired concentration in 2% DMSO and pre-incubated with NudF (125 nM) at ambient temperature for 30 min. 2 µL ADP-ribose solution was added to all wells at a final concentration of 2 µM and incubated with drug and NudF for 30 min. Following the incubation, 5 µL of AMP-Glo™ Reagent I was added to wells, mixed gently and the plates incubated for 60 min. Before the end of this incubation, and immediately before use, AMP-Glo™ Reagent II was added to the Kinase-Glo® One solution (at a ratio of 1:100 v/v) and 10 µL of this mixture added to all wells, mixed gently and the plates incubated for another 60 min. The luminescence was detected by a Synergy TM H1 Microplate Reader. Compounds that passed the counter screen will be selected for activity confirmation where they were preincubated with NudF (125 nM) alone or together with either Mac1 (1.7 nM) or MacroD2 (2 nM) for 30 min and then reacted with ADP-ribosylated substrates (20 µM) for 30 min.

The nsp3 SARS-CoV-2 nucleotide sequence (positions 2720-8554 of NCBI Reference Sequence NC_045512.2) was aligned to 449,612 full-length SARS-CoV-2 genomes from the COVID-19 Data Portal in R using the package Biostrings pairwiseAlignment function. 3 The aligned sequences were translated and trimmed to amino acid positions 207-373 of the nsp3 protein, which corresponds to the Mac1 macrodomain as in 6Z5T. Poor-quality sequences, S10 defined as having greater than five mismatched or missing amino acids within the 167-amino acid macrodomain, were removed. The remaining 440,212 high-quality macrodomain sequences were then used to calculate mutation frequencies. All code necessary to reproduce the analysis as well as processed intermediate data are available at https://github.com/vbusa1/nsp3_macrodomain.

The crystal structures of Mac1 (65ZT) and MacroD2 (4IQY) were used to generate a structurebased sequence alignment using ESPRESSO a subroutine of T-Coffee. 4 Residues in 5Å proximity of the ADPr binding site were defined as the ADPr-binding pocket and compared for identity. The conservation plot was generated using the Consurf server 5 using default values and the Mac1 (6Z5T) as a template. Vaccum electrostatics potential were calculated using 

The following receptors were utilized for docking 6Z5T and 4IQY as a representative for SARS-CoV-2 and human MacroD2. Dasatinib was docked using FRED with a conformer library generated with Omega2 5-7 using a high resolution grid. Visualization and analysis were carried out in Vida v4.4.0 (OpenEye Scientific Software). While many of the residues lining the active site pocket are conserved between the two proteins, the electrostatic surface potential varies significantly as well as the pocket size. Importantly, the ribose moiety in the MacroD2 is located in a more neutrally charged region, while the SARS-CoV-2 region is strongly positively charged.

Similar charge reversal differences were observed in the adenine binding region, where the SARS-CoV-2 region is negatively charged while the MacroD2 is positively charged. These S11 charge differences are likely the reason for very weak interaction of dasatinib with MacroD2.

Additionally, the SARS-CoV-2 pocket is larger with approximately 1300 Å 3 in size while the Human MacroD2 pocket is only 850 Å 3 large. While ADP-ribose in both structures is stabilized by multiple polar interactions, dasatinib only makes two polar contacts based on our lowest energy binding pose. The majority of the contacts are of hydrophobic nature while the hydroxyl of sidechain Asp226 and the backbone oxygen of Leu 330 are hydrogen bonding with dasatinib.

All interactions were performed on a Biacore T200 instrument at 25˚C using an HBS-P buffer (10 mM Hepes, 150 mM NaCl, 3 µM EDTA, 0.05% Surfactant P20, pH 7.4) supplemented with 0.5% DMSO. Proteins were covalently coupled to a CM5 chip at high density > 30000 RUs.

Analytes were passed over the flow cells at six twofold dilutions with 60s contact and 120s dissociation time at a 30 µL/min flow rate. After each injection the flow cells were regenerated with a pulse of 10 mM Glycine pH 9. Analysis was carried out with Scrubber2 (BioLogic Software, http://www.biologic.com.au/scrubber.html) using the double referencing method and correcting for DMSO differences in the analyte samples. Data was corrected and normalized for the differences in molecular weight of the ligands as well as the captured protein molecular weights.

Data visualization was performed in Prism 9.0 (GraphPad).

Experiments were performed essentially as described by Virdi et al. (2020) . Briefly, a master mix of MOPS pH 7.0 (20 mM), NaCl (25 mM), SYPRO Orange (6.25X) and Mac1 (5 µM) was prepared and 19 µL was dispensed into each well of a 96-well PCR plate. Compound (500 µM, 1 µL of a 10 mM stock, n = 3) was added, then the plate was inserted into a 7500 Fast RT-qPCR (Applied Biosystems). Samples were incubated with a temperature gradient from 25 °C to 95 °C 

Fig. S3 | Determining optimal assay parameters for high-throughput screening. (A) pH dependence of luminescent signal from the ADPr-Glo assay. pH 7 has the highest signal-tonoise ratio. (B) AMP generated as a function of NudF concentration (15 nM -1 µM). 125 nM was used for all kinetic assays and drug screening. Therefore, NudF is used in a large excess of the macrodomain such that the conversion of ADP-ribose to AMP is not the rate-limiting step. (C) The effect of DMSO concentration on the luminescent signal from the ADPr-Glo assay. (D) AMP generated as a function of SARS-CoV-2 macrodomain concentration (0.1 nM -2 nM). The linear range is ≤ 1 nM, which was used for all kinetic assays and drug screening. Electrostatic surface potential of ADP-ribose and dasatinib in two orientations. The overall shapes of the two molecules are comparable though distinct in their chemical properties. We note that the large negative ring of ADP-ribose snuggly interacts with the corresponding countercharge in the binding pocket, but dasatinib provides only a small negatively charged area in the corresponding location.

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-NCoV and Naming It SARS-CoV-2

Drug Discovery Strategies for SARS-CoV-2

Macrodomains: Structure, Function, Evolution, and Catalytic Activities

Viral Macrodomains: Unique Mediators of Viral Replication and Pathogenesis

Macrodomain ADP-Ribosylhydrolase and the Pathogenesis of Infectious Diseases

Proximal ADP-Ribose Hydrolysis in Trypanosomatids Is Catalyzed by a Macrodomain

Macro Domain from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Is an Efficient ADP-Ribose Binding Module: CRYSTAL STRUCTURE AND BIOCHEMICAL STUDIES

Macrodomain-Containing Proteins Are New Mono-ADP-Ribosylhydrolases

A Family of Macrodomain Proteins Reverses Cellular Mono-ADP-Ribosylation

Viral Macro Domains Reverse Protein ADP-Ribosylation

ADP-Ribosylhydrolase Activity of Chikungunya Virus Macrodomain Is Critical for Virus Replication and Virulence

The Conserved Macrodomains of the Non-Structural Proteins of Chikungunya Virus and Other Pathogenic Positive Strand RNA Viruses Function as Mono-ADP-Ribosylhydrolases

The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection

Molecular Basis for ADP-Ribose Binding to the Mac1 Domain of SARS-CoV-2 Nsp3

Ahel, I. Viral Macrodomains: A Structural and Evolutionary Assessment of the Pharmacological Potential

The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase

Biophysical, and Biochemical Elucidation of the SARS-CoV-2 Nonstructural Protein

ADP-Ribosyl-Binding and Hydrolase Activities of the Alphavirus NsP3 Macrodomain Are Critical for Initiation of Virus Replication

Both ADP-Ribosyl-Binding and Hydrolase Activities of the Alphavirus NsP3 Macrodomain Affect Neurovirulence in Mice

Mouse Hepatitis Virus Liver Pathology Is Dependent on ADP-Ribose-1''-Phosphatase, a Viral Function Conserved in the Alpha-like Supergroup

An MHV Macrodomain Mutant Predicted to Lack ADP-Ribose Binding Activity Is Severely Attenuated, Indicating Multiple Roles for the Macrodomain in Coronavirus Replication

Stress Granule Formation, Disassembly, and Composition Are Regulated by Alphavirus ADP-Ribosylhydrolase Activity

New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays

Ahel, I. Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified through Crystallographic Screening and Computational Docking

Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV

Exploring Protein Hotspots by Optimized Fragment Pharmacophores

Dasatinib Induces Notable Hematologic and Cytogenetic Responses in Chronic-Phase Chronic Myeloid Leukemia after Failure of Imatinib Therapy

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Tricarbonylchromium(0) Promoted Stereoselective Cyclisations of the N-3,4-Dimethoxyphenethyl Derivatives of the 1-Phenyl Ethanolamines Halostachine, Ephedrine and Pseudoephedrine to 1-Phenyl-N-Methyl-7,8-Dimethoxy-1,2,4,5-Tetrahydrobenzazepines

A Novel Method for Fast and Accurate Multiple Sequence Alignment

An Improved Methodology to Estimate and Visualize Evolutionary Conservation in Macromolecules

Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database

Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures

Docking Performance on Standardized Datasets

SARS-CoV-2 SARS-CoV MERS-CoV HCoV-299E HCoV-NL63 HCoV-OC43

SARS-CoV-2 SARS-CoV MERS-CoV HCoV-299E HCoV-NL63 HCoV-OC43

While the fragments have been crystallized at very high concentrations, we did not observe a significant dose-dependent binding to Mac1 at the concentrations tested, except for ZINC263392672 at its highest concentration. Notably, ZINC263392672 also inhibited weakly Mac1 in a dose-dependent manner (panel A). Clear binding of dasatinib was observed to His-Sumo-Mac1 but not His-Sumo alone, indicating S19 specific binding to SARS-CoV-2 Mac1. (C) Differential scanning fluorimetry of